Status:
UNKNOWN
Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stage Small Cell Lung Cancer
Lead Sponsor:
Hunan Province Tumor Hospital
Conditions:
Extensive-stage Small-cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recrui...
Eligibility Criteria
Inclusion
- Patients must be ≥18 years.
- Provision of fully informed consent prior to any study specific procedures.
- Patients with extensive stage SCLC diagnosed by pathology (as staged by the American Veterans Lung Cancer Association (VALG)), who do not have an imaging response during first-line treatment with PD-(L)1 inhibitors, or who progress after imaging reactions on first-line therapy (the most recent regimen prior to enrollment must contain PD-(L)1 inhibitors).
- According to the RECIST 1.1 standard, the patient must have at least one measurable lesion.
Exclusion
- None
Key Trial Info
Start Date :
December 25 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT05991180
Start Date
December 25 2023
End Date
December 31 2025
Last Update
December 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hunan Cancer hospital
Changsha, Hunan, China